{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:20:43Z","timestamp":1768342843619,"version":"3.49.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"S1 Biopharma,Inc."},{"name":"S1 Biopharma,Inc"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Prior medication treatment for hypoactive sexual desire disorder (HSDD) in women has left about half the subjects without benefit. Lorexys (LOR), a proprietary combination of the stimulating\/excitatory dopamine-norepinephrine reuptake inhibitor bupropion (BUP) and the sedating\/inhibitory serotonergic agonist-antagonist trazodone (TRZ), was developed as a multifunctional solution for this problem.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>Test efficacy, safety, and tolerability of LOR in a range of doses in a combined phase IB\/IIA study in premenopausal outpatients with HSDD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Otherwise healthy premenopausal women from 25\u201350 years of age with HSDD were tested in an open-label, active-control, one-way crossover study, with three 4-week treatments of extended-release TRZ and\/or sustained-release BUP. Evaluations were made before and after each treatment. A washout of at least a week followed each treatment. The order of treatments was a standard dose of BUP; a subtherapeutic dose of BUP and TRZ (LOR-low); and a threshold-therapeutic dose of BUP and TRZ (LOR-mod). A midpoint interim analysis was planned to consider adapting doses for efficacy or safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measure<\/jats:title>\n                  <jats:p>The primary efficacy measure was the Female Sexual Function Index, Desire domain; the main secondary efficacy measures included the Female Sexual Distress Scale-Revised 13th item, on bother about low desire, and a Patient\u2019s Global Impression of Change. The main outcome comparison was the proportions of responders. Safety measures were elicited adverse events, Epworth Sleepiness Scale, Columbia Suicide Severity Rating Scale 6-item SCREEN version, vital signs, electrocardiograms, and standard laboratory tests.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Interim analysis did not require altering doses. Most evaluable subjects responded to LOR-mod (at the standard thresholds for response based on minimum clinically relevant difference from baseline, 79% on Female Sexual Function Index, Desire domain, 87% on Female Sexual Distress Scale-Revised Item 13, and 79% on Patient\u2019s Global Impression of Change; each P &amp;lt; .05 vs BUP). As expected, close to half responded to BUP (38%, 45%, and 52%, respectively). Response to LOR-low was intermediate (not significant vs BUP). Sensitivity analyses to compensate for carryover effects supported the efficacy of LOR-mod. Elicited adverse events showed the expected profile of TRZ, but led to no sedative-type dropouts or worsening on the Epworth Sleepiness Scale.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>The open-label 1-way crossover design of this phase IB\/IIA study limits conclusions, but the consistency of responder analyses showing superiority of LOR-mod dose over control, and the lack of central depressant dropouts, favor further development in double-blind placebo-control trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strength &amp; Limitations<\/jats:title>\n                  <jats:p>Strengths include large margins of efficacy over control agent, rapid onset of action, and rigorous safety assessment. Limitations are open-label, cross-over design\/lack of placebo control and 1-month duration of exposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Moderate-dose LOR was generally well-tolerated and was significantly more effective than BUP (active control). The results seem highly favorable compared to previously tested agents.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.jsxm.2019.09.005","type":"journal-article","created":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T10:46:56Z","timestamp":1572778016000},"page":"1885-1894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women"],"prefix":"10.1093","volume":"16","author":[{"given":"Robert E.","family":"Pyke","sequence":"first","affiliation":[{"name":"President, Pykonsult, LLC, 23 Eastview Drive , New Fairfield, CT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita H.","family":"Clayton","sequence":"additional","affiliation":[{"name":"University of Virginia, 2955 Ivy Road, Suite 210 , Charlottesville, VA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,10,30]]},"reference":[{"key":"2023012309485861900_bib1","first-page":"175","article-title":"Clinically relevant changes in sexual desire, satisfying sexual activity and personal distress as measured by the profile of female sexual function, sexual activity log, and personal distress scale in postmenopausal women with hypoactive sexual desire disorder","volume":"6","author":"DeRogatis","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"2023012309485861900_bib2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.sxmr.2017.05.003","article-title":"Flibanserin efficacy and safety in premenopausal women with generalized acquired hypoactive sexual desire disorder","volume":"5","author":"Fisher","year":"2017","journal-title":"Sex Med Rev"},{"key":"2023012309485861900_bib3","article-title":"Bremelanotide (BMT) for hypoactive sexual desire disorder (HSDD): Efficacy analyses from the RECONNECT study. Pipeline Presentation","author":"Clayton","year":"30, 2017"},{"key":"2023012309485861900_bib4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/01.AOG.0000533221.21767.0a","article-title":"Efficacy of bremelanotide for HSDD in women: RECONNECT open-label extension phase results [8Q]","volume":"131","author":"Clayton","year":"2018","journal-title":"Obstet Gynecol"},{"key":"2023012309485861900_bib5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.mayocp.2016.09.018","article-title":"Hypoactive Sexual Desire Disorder, International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review","volume":"92","author":"Goldstein","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2023012309485861900_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3810\/pgm.2014.03.2744","article-title":"Antidepressants and sexual dysfunction: Mechanisms and clinical implications","volume":"126","author":"Clayton","year":"2014","journal-title":"Postgrad Med"},{"key":"2023012309485861900_bib7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/00325481.2017.1249265","article-title":"A\u00a0review of trazodone use in psychiatric and medical conditions","volume":"129","author":"Khouzam","year":"2017","journal-title":"Postgrad Med"},{"key":"2023012309485861900_bib8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.jcp.0000125686.20338.c1","article-title":"Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women","volume":"24","author":"Segraves","year":"2004","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"Suppl 2","key":"2023012309485861900_bib9","first-page":"1068","article-title":"The efficacy of bupropion and trazodone for treatment of hypoactive sexual desire disorder and orgasm dysfunction in non-depressed women, Poster P-02-176 in XIV World Congress of Psychiatry, September 20\u201325, 2008, Prague, Czech Republic","volume":"104","author":"Zourkova","year":"2008","journal-title":"J\u00a0Czech and Slovak Psych"},{"issue":"Suppl 4","key":"2023012309485861900_bib10","first-page":"32","article-title":"Bupropion sustained release: side effect profile","volume":"59","author":"Settle","year":"1998","journal-title":"J\u00a0Clin Psychiatry"},{"key":"2023012309485861900_bib11","first-page":"20","article-title":"Extended-release trazodone in major depressive disorder: A randomized, double-blind, placebo-controlled study","volume":"6","author":"Sheehan","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"key":"2023012309485861900_bib12","first-page":"3096","article-title":"Sexual desire and the Female Sexual Function Index (FSFI): A sexual desire cutpoint for clinical interpretation of the FSFI in women with and without hypoactive sexual desire disorder","volume":"7","author":"Gerstenberger","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"2023012309485861900_bib13","first-page":"357","article-title":"Validation of the Female Sexual Distress Scale-Revised for assessing distress in women with hypoactive sexual desire disorder","volume":"5","author":"Derogatis","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"2023012309485861900_bib14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A\u00a0new method for measuring daytime sleepiness: The Epworth Sleepiness Scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"2023012309485861900_bib15","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"2023012309485861900_bib16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: Validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J\u00a0Gen Intern Med"},{"key":"2023012309485861900_bib17","article-title":"Task Force on DSM-IV","author":"DSM-IV-TR; American Psychiatric Association, American Psychiatric Association","year":"2000"},{"key":"2023012309485861900_bib18","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","article-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013"},{"key":"2023012309485861900_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2466\/pr0.1997.81.2.419","article-title":"Reconsideration of the Locke-Wallace Marital Adjustment Test: Is it still relevant for the 1990s?","volume":"81","author":"Freeston","year":"1997","journal-title":"Psychol Rep"},{"key":"2023012309485861900_bib20","article-title":"Boehringer Ingelheim Pharmaceuticals Inc, Flibanserin Advisory Committee Briefing Document, June 2010"},{"key":"2023012309485861900_bib21","article-title":"Graph Pad QuickCals"},{"key":"2023012309485861900_bib22","first-page":"2354","article-title":"Female clitoral priapism: An over-the-counter option for management","volume":"11","author":"Unger","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"2023012309485861900_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11325-016-1417-x","article-title":"The use of an online Epworth Sleepiness Scale to assess excessive daytime sleepiness","volume":"21","author":"Boyes","year":"2017","journal-title":"Sleep Breath"},{"key":"2023012309485861900_bib24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.sxmr.2017.11.008","article-title":"Assessment of sexual desire for clinical trials of women with hypoactive sexual desire disorder: Measures, desire-related behavior, and assessment of clinical significance","volume":"6","author":"Pyke","year":"2018","journal-title":"Sex Med Rev"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609519314274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609519314274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/12\/1885\/48589575\/jsm_16_12_1885.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/12\/1885\/48589575\/jsm_16_12_1885.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T10:27:18Z","timestamp":1674469638000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/16\/12\/1885\/6980721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,30]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,10,30]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.09.005","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,10,30]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}